转移性结直肠癌中的循环肿瘤细胞：不同富集方法的疗效和可行性。

Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods.

机构信息

Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR Vienna)/CEADDP, Vienna, Austria.

出版信息

Cancer Lett. 2010 Jul 1;293(1):117-23. doi: 10.1016/j.canlet.2010.01.003. Epub 2010 Feb 18.

DOI:10.1016/j.canlet.2010.01.003

PMID:20167419

Abstract

Comprehensive in vitro and in vivo studies comparing EpCAM-based methods with other cytometric CTC enrichment technologies in metastatic colorectal cancer (mCRC) patients are lacking. We compare four manual cytometric methods to detect CTCs in vitro and in mCRC patients. The EpCAM-based technology, MACS HEA MicroBeads((R)), showed a significant better tumor cell recovery rate compared to other cytometric methods (p-value<0.0001). CTCs of 38 mCRC patients were enriched with MACS HEA MicroBeads(R). Progression-free survival did significantly differ between mCRC patients without detectable and with >or= 1 CTCs (p=0.007). CTC enrichment with EpCAM coupled antibodies is superior to other cytometric methods and is a feasible method for CTC detection in mCRC patients.

摘要

缺乏比较上皮细胞黏附分子（EpCAM）为基础的方法与其他细胞计量学循环肿瘤细胞（CTC）富集技术在转移性结直肠癌（mCRC）患者中的应用的全面的体外和体内研究。我们比较了四种手动细胞计量学方法来检测体外和 mCRC 患者中的 CTC。基于 EpCAM 的技术，MACS HEA MicroBeads((R))，与其他细胞计量学方法相比，显示出明显更好的肿瘤细胞回收率（p 值<0.0001）。用 MACS HEA MicroBeads(R)富集了 38 名 mCRC 患者的 CTC。无检测到 CTC 和检测到 >或=1 CTC 的 mCRC 患者之间的无进展生存期有显著差异（p=0.007）。EpCAM 偶联抗体的 CTC 富集优于其他细胞计量学方法，是 mCRC 患者 CTC 检测的一种可行方法。